A randomized phase II study of the efficacy and safety of combination of Bevacizumab/Pemetrexed versus Pemetrexed maintenance therapy in First-Line treatment of elderly patients with advanced or recurrent post-operative non-squamous and non-small cell lung cancer who received Bevacizumab / Pemetrexed induction therapy.
Phase 2
- Conditions
- non-squamous non-small cell lung cancer
- Registration Number
- JPRN-UMIN000013122
- Lead Sponsor
- Department of Pulmonary Medicine, School of Medicine, Keio University, Tokyo, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with symptomatic Brain metastasis 2)History of hemoptysis 3)History of thoracic radiotherapy 4)active infection 5)fever 6)severe complication 7)massive pleural effusion or ascites 8)active concomitant malignancy 9)history of severe drug allergy 10)uncontrolled peptic ulcer 11)Current or previous history of GI perforation 12)Patients with therapeutic anticoagulopathy 13)those judged not suitable by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method